Blue Trust Inc. Purchases 341 Shares of DaVita Inc. (NYSE:DVA)

Blue Trust Inc. grew its position in shares of DaVita Inc. (NYSE:DVA) by 150.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 567 shares of the company’s stock after acquiring an additional 341 shares during the quarter. Blue Trust Inc.’s holdings in DaVita were worth $87,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Epoch Investment Partners Inc. bought a new stake in DaVita during the fourth quarter worth $55,100,000. Invesco Ltd. grew its holdings in DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock worth $237,716,000 after buying an additional 275,284 shares in the last quarter. Iron Triangle Partners LP bought a new stake in DaVita during the fourth quarter worth $38,946,000. Amundi grew its holdings in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in DaVita by 14,695.8% during the first quarter. GAMMA Investing LLC now owns 234,809 shares of the company’s stock worth $35,919,000 after buying an additional 233,222 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.4%

DVA stock opened at $140.41 on Thursday. The stock’s fifty day simple moving average is $139.42 and its two-hundred day simple moving average is $149.73. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1-year low of $131.76 and a 1-year high of $179.60. The stock has a market cap of $10.60 billion, a P/E ratio of 13.92, a P/E/G ratio of 0.97 and a beta of 1.11.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The firm had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.22 billion. During the same quarter in the prior year, the firm earned $2.26 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. Analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on DVA shares. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Truist Financial cut their price objective on DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.